Lates News

PACIFIC released a research report on April 30th, giving a buy rating to Yuandong Biotechnology (688513.SH). The main reasons for the rating include: 1) steady growth of main products and significant contribution from new products; 2) actively promoting mergers and collaborations to accelerate the development of innovative drugs. (Daily Economic News)